Abstract
The limited supply and relative cost of Actinium-225 can be prohibitive to researchers in the field of Targeted Alpha Therapy (TAT). Currently, there are only three sources (Institute for Transuranium Elements (ITU), Germany; Oak Ridge National Laboratory (ORNL), USA; and Institute of Physics and Power Engineering (IPPE), Russia) of commercially available, isotopically pure Actinium-225. Two Thorium-229/Actinium-225 generators have been developed at Canadian Nuclear Laboratories (CNL) by isolation of Thorium-229 from an aged Uranium-233 supply. The generators are capable of producing 3-6 mCi of isotopically pure Actinium-225 monthly. The Actinium-225 yielded from the generators has been used in radiolabelling experiments with novel Actinium-225 chelates and conjugated monoclonal antibodies, and has supported pre-clinical studies utilizing Actinium-225 labelled targeting vectors. Radiolabelling experiments have determined that the Actinium-225 material produced from the generators is suitable for use in preparation of pre-clinical scale TAT agents.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
